结合雌激素(Estrogens, Conjugated) - 药物靶点：ER_在研适应症：性交困难，乳腺癌，低雌激素_专利_临床

To study the utility of Estrogen Receptor and Progesterone Receptor expression as an immunohistochemical predictive markers for tumour behaviour in comparison to histopathological parameters and Tumour, Lymph Node and Metastatic staging in colorectal carcinoma - Nil

开始日期2024-06-10

申办/合作机构-

IRCT20240207060932N1 / Suspended临床3期IIT

Comparison of the effects of Persicaria hydropiper vaginal cream based on coconut oil and sesame oil with conjugated estrogen vaginal cream and placebo on vaginal atrophy and sexual function of postmenopausal women.

开始日期2024-04-08

申办/合作机构-

IRCT20230611058454N1 / Recruiting临床3期IIT

Comparison of the effect of misoprostol alone and misoprostol together with vaginal estrogen in preparing the cervix and induction of labor in term pregnancies

开始日期2023-07-23

申办/合作机构

Tehran University of Medical Sciences

100 项与结合雌激素相关的临床结果

登录后查看更多信息

100 项与结合雌激素相关的转化医学

登录后查看更多信息

100 项与结合雌激素相关的专利（医药）

登录后查看更多信息

1,509

项与结合雌激素相关的文献（医药）

2024-10-01·Human genetics

Identification of TACSTD2 as novel therapeutic targets for cisplatin-induced acute kidney injury by multi-omics data integration

Article

作者: Wang, Yinhuai ; Dong, Zheng ; Liu, Jiachen ; Deng, Fei ; Dai, Yingbo ; Deng, Zebin

Cisplatin-induced acute kidney injury (CP-AKI) is a common complication in cancer patients. Although ferroptosis is believed to contribute to the progression of CP-AKI, its mechanisms remain incompletely understood. In this study, after initially processed individual omics datasets, we integrated multi-omics data to construct a ferroptosis network in the kidney, resulting in the identification of the key driver TACSTD2. In vitro and in vivo results showed that TACSTD2 was notably upregulated in cisplatin-treated kidneys and BUMPT cells. Overexpression of TACSTD2 accelerated ferroptosis, while its gene disruption decelerated ferroptosis, likely mediated by its potential downstream targets HMGB1, IRF6, and LCN2. Drug prediction and molecular docking were further used to propose that drugs targeting TACSTD2 may have therapeutic potential in CP-AKI, such as parthenolide, progesterone, premarin, estradiol and rosiglitazone. Our findings suggest a significant association between ferroptosis and the development of CP-AKI, with TACSTD2 playing a crucial role in modulating ferroptosis, which provides novel perspectives on the pathogenesis and treatment of CP-AKI.

2024-09-16·CLIMACTERIC

Effect of hormone therapy on personality traits: preliminary evidence in older men and women.

Article

作者: Terracciano, Antonio ; Schroeder, Rachel A ; Costa, Paul T ; Dobs, Adrian ; Resnick, Susan M ; Mordecai, Kristen L ; Maki, Pauline M ; Durso, Samuel C

OBJECTIVE:

Findings concerning the effects of hormone therapy (HT) on cognition and dementia are mixed, with some trials suggesting increased harm at older ages. Personality, like cognition, changes with dementia, but no clinical trials to date have examined the effects of HT on personality traits. This study aimed to determine the effects of HT on personality traits in older men and women.

METHOD:

Secondary data analysis was performed from randomized, double-blind, placebo-controlled cross-over studies of menopausal HT in women and testosterone therapy (TT) in men. Participants were community-dwelling cognitively normal adults (mean age = 75.2 years), including 29 men and 22 women. Three months of hormone intervention (for women, 0.625 mg/day conjugated equine estrogen with or without 2.5 mg/day medroxyprogesterone acetate; for men, 200 mg intramuscular testosterone enanthate every 2 weeks) were crossed over with 3 months of identical placebo with a 3-month washout between intervention phases. The main outcome measure was neuroticism and conscientiousness personality domains and facets assessed with the Revised NEO Personality Inventory (NEO-PI-R) after the active and placebo intervention phases.

RESULTS:

In linear mixed-effect models, HT in women decreased conscientiousness (p < 0.01) and the conscientiousness facet of achievement striving (p < 0.01), and increased vulnerability, a facet of neuroticism (p < 0.05). Testosterone in men decreased conscientiousness (p < 0.05) and the conscientiousness facet of dutifulness (p < 0.05), and increased vulnerability (p < 0.05).

CONCLUSION:

In a preliminary study of healthy older adults, HT and TT formulations produced adverse changes in vulnerability and conscientiousness facets that parallel personality changes in dementia.

2024-09-01·JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Metabolism of endogenous and exogenous estrogens in women

Review

作者: Stanczyk, Frank Z

Estrogens regulate important processes in reproductive, skeletal, cardiovascular, and central nervous systems that impact women's overall health. Understanding endogenous and exogenously administered estrogen metabolism is vital to determining therapeutic estrogen levels. The present review provides an overview of estrogen metabolites formed in non-pregnant and pregnant women, and those resulting from exogenous estrogen administration. There are four principal endogenous estrogens: estrone (E₁), estradiol (E₂), estriol (E₃), and estetrol (E₄). E₄, which is produced only in pregnancy, has emerged recently as an estrogen with significant therapeutic potential. E₁, E₂, and E₃ undergo extensive metabolism primarily through phase I (hydroxylation, oxidation, reduction) and phase II (primarily conjugation) reactions, whereas E₄ undergoes only phase II reactions. Exogenous estrogens commonly used for menopausal treatment and/or contraception, including micronized E₂, conjugated equine estrogens, and ethinyl estradiol, also undergo phase I and phase II reactions, but differ widely in the types of metabolites formed. The mechanisms by which estrogen metabolites are formed and their excretion in urine, bile, and feces, are still poorly understood. We highlight areas that require further research to foster a better understanding of how estrogen metabolism impacts dosing of oral estrogens for therapeutic use, as well as the physiological regulation of endogenous estrogens.

26

项与结合雌激素相关的新闻（医药）

2024-10-31

·GlobeNewswire-Health Care

New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast cancer

ItovebiTM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and fulvestrant alone in the INAVO120 study1 The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR-positive, HER2-negative breast cancer with a PIK3CA mutation, one of the most commonly mutated genes in HR-positive disease2 Basel, 31 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the positive phase III INAVO120 results, evaluating ItovebiTM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant were published in the New England Journal of Medicine.1 The United States Food and Drug Administration (FDA) recently approved Itovebi in combination with palbociclib and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. Data from INAVO120 are also being used for filing submissions to other global health authorities, including the European Medicines Agency. “With a doubling of progression-free survival and consistent benefits in people whose disease had spread to multiple challenging-to-treat locations, including the liver and lungs, these INAVO120 data are significant for patients,” said Komal Jhaveri, M.D., section head for the endocrine therapy research portfolio and clinical director of the early drug development service at Memorial Sloan Kettering Cancer Center and one of the principal investigators of the INAVO120 study. “I’m confident this Itovebi-based regimen could become a new first-line standard of care for this patient population with one of the most commonly mutated genes in metastatic breast cancer, associated with a poor prognosis.” Results showed the Itovebi-based regimen reduced the risk of disease worsening or death (progression-free survival [PFS]) by 57% compared to palbociclib and fulvestrant alone (15.0 months vs. 7.3 months; hazard ratio [HR]=0.43, 95% CI: 0.32-0.59, p<0.001).1 PFS benefit was consistent across all pre-specified subgroups, including people whose disease had spread to three or more locations, which is characterised as difficult-to-treat disease.1 Overall survival (OS) data were immature at the time of analysis, but a clear positive trend has been observed (stratified HR=0.64, 95% CI: 0.43-0.97, p=0.03 [boundary of 0.0098]).1 Follow-up for OS will continue to the next analysis.1 “Publication of these phase III results in the New England Journal of Medicine further highlights the transformative potential of the Itovebi-based regimen,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This new treatment exemplifies our ambition to target specific disease pathways more effectively and improve outcomes in people with breast cancer, while also emphasising the importance of comprehensive testing for mutations like PIK3CA at the time of diagnosis.” The PIK3CA mutation is found in approximately 40% of HR-positive metastatic breast cancers and is associated with a poor prognosis.2,3 Historically, the use of PI3K targeted therapy in the first-line advanced setting has been limited and therefore testing for PIK3CA mutations is not common at the time of diagnosis.4 Early biomarker testing with an FDA-approved test, such as Foundation Medicine’s FoundationOne®Liquid CDx, before first-line treatment is crucial to help identify people who may benefit from targeted therapy, such as Itovebi.4,5 Itovebi is currently being investigated in three company-sponsored phase III clinical studies (INAVO120, INAVO121, INAVO122) in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations.6-8 We are exploring additional studies in breast cancer and other tumour types with the hope of bringing the benefit of this targeted therapy to more people with PIK3CA mutations and addressing patient unmet needs. About the INAVO120 studyThe INAVO120 study [NCT04191499] is a phase III, randomised, double-blind, placebo-controlled study evaluating the efficacy and safety of Itovebi (inavolisib) in combination with palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in people with PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer whose disease progressed during treatment or within 12 months of completing adjuvant endocrine therapy and who have not received prior systemic therapy for metastatic disease.6 The study included 325 patients, who were randomly assigned to either the investigational or control treatment arm.6 The primary endpoint is progression-free survival, as assessed by investigators, defined as the time from randomisation in the clinical trial to the time when the disease progresses, or a patient dies from any cause.6 Secondary endpoints include overall survival, objective response rate, and clinical benefit rate.6 Beyond INAVO120, Itovebi is currently being investigated in two additional company-sponsored phase III clinical studies in PIK3CA-mutated locally advanced or metastatic breast cancer in various combinations:7,8 in combination with fulvestrant versus alpelisib plus fulvestrant in HR-positive/HER2-negative breast cancer post cyclin-dependent kinase 4/6 inhibitor and endocrine combination therapy (INAVO121; NCT05646862), andin combination with pertuzumab plus trastuzumab for subcutaneous injection (SC) versus pertuzumab plus trastuzumab for SC and optional physician's choice of endocrine therapy as a maintenance treatment in HER2-positive disease (INAVO122; NCT05894239). About hormone receptor (HR)-positive breast cancerHR-positive breast cancer is the most prevalent type of all breast cancers, accounting for approximately 70% of cases.9,10 A defining feature of HR-positive breast cancer is that its tumour cells have receptors that attach to one or both hormones – oestrogen or progesterone – which can contribute to tumour growth. People diagnosed with HR-positive metastatic breast cancer often face the risk of disease progression and treatment side effects, creating a need for additional treatment options.10-12 The PI3K signalling pathway is commonly dysregulated in HR-positive breast cancer, often due to activating PIK3CA mutations, which have been identified as a potential mechanism of intrinsic resistance to standard of care endocrine therapy in combination with cyclin-dependent kinase 4/6 inhibitors.3 About Roche in breast cancerRoche has been advancing breast cancer research for more than 30 years with the goal ofhelping as many people with the disease as possible. Our medicines, along with companiondiagnostic tests, have contributed to bringing breakthrough outcomes in human epidermal growth factor 2-positive and triple-negative breast cancers. As our understanding of breast cancer biology rapidly improves, we are working to identify new biomarkers and approaches to treatment for other subtypes of the disease, including oestrogen receptor-positive breast cancer, which is a form of hormone receptor-positive breast cancer, the most prevalent type of all breast cancers.9,10 About RocheFounded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law.References[1] Turner NC, et al. Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer. NEJM. 2024;391(17).[2] Fillbrunn M, et al. PIK3CA mutation status, progression and survival in advanced HR+/HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22:1002.[3] Anderson E, et al. A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer. Int J Breast Cancer. 2020;2020:3759179.[4] Princic N, et al. Abstract P1-18-18: PIK3CA mutation testing prevalence among post-menopausal (PM) women with hormone receptor positive and human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC) using real world data. Cancer Res. 2020;80(4):P1-18-18.[5] Wales Cancer Network. PIK3CA-mutated breast cancer clinical guidance document [Internet; cited 2024 October]. Available from: https://executive.nhs.wales/functions/networks-and-planning/cancer/wcn-documents/mutated-breast-cancer-clinical-guidance-document//.[6] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) [Internet; cited 2024 October]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04191499.[7] ClinicalTrials.gov. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) [Internet; cited 2024 October]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05646862.[8] ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer [Internet; cited 2024 October]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05894239.[9] National Cancer Institute: Surveillance, Epidemiology and Ends Result Program. Cancer Stat Facts: Female Breast Cancer Subtypes [Internet; cited 2024 October]. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html.[10] Lim E, et al. The natural history of hormone receptor-positive breast cancer. Oncology (Williston Park). 2012;26(8):688-94,696.[11] Tomas R and Barrios CH. Optimal management of hormone receptor positive metastatic breast cancer in 2016. Ther Adv Med Oncol. 2015;7(6):304-20.[12] Galipeau N, et al. Understanding key symptoms, side effects, and impacts of HR+/HER- advanced breast cancer: qualitative study findings. J Patient-Rep Outcomes. 2019;3(1):10. Dr. Jhaveri has financial interests related to Roche and Genentech. Roche Global Media RelationsPhone: +41 61 688 8888 / e-mail: media.relations@roche.com Hans Trees, PhDPhone: +41 79 407 72 58 Sileia UrechPhone: +41 79 935 81 48 Nathalie AltermattPhone: +41 79 771 05 25 Lorena CorfasPhone: +41 79 568 24 95 Simon GoldsboroughPhone: +44 797 32 72 915 Karsten KleinePhone: +41 79 461 86 83 Nina MählitzPhone: +41 79 327 54 74 Kirti PandeyPhone: +49 172 6367262 Yvette PetillonPhone: +41 79 961 92 50 Dr Rebekka SchnellPhone: +41 79 205 27 03 Attachment 31102024_Itovebi NEJM_en

临床3期临床结果上市批准

2024-09-10

·drugs

Review Weighs Treatments for Genitourinary Symptoms of Menopause

TUESDAY, Sept. 10, 2024 -- Vaginal estrogen, vaginal dehydroepiandrosterone (DHEA), oral ospemifene, and vaginal moisturizers may be beneficial for some genitourinary symptoms of menopause (GSM), according to a review published online Sept. 10 in the Annals of Internal Medicine . Elisheva R. Danan, M.D., M.P.H., from the University of Minnesota in Minneapolis, and colleagues examined the effectiveness and harms of vaginal estrogen, nonestrogen hormone therapies, and vaginal moisturizers for treatment of GSM in a systematic review of randomized controlled trials (RCTs). A total of 46 RCTs assessing vaginal estrogen, nonestrogen hormones, vaginal moisturizers, or multiple interventions were identified from 11,993 citations. The researchers found that vaginal estrogen may improve vulvovaginal dryness, dyspareunia , the most bothersome symptom, and treatment satisfaction compared with placebo or no treatment. Vaginal DHEA may improve dryness, dyspareunia, and distress, bother, or interference from genitourinary symptoms compared with placebo; oral ospemifene may improve dryness, dyspareunia, and treatment satisfaction; and dryness may also be improved by vaginal moisturizers (all low certainty of evidence [COE]). No benefit or uncertain effects (low and very low COE, respectively) may be provided by vaginal testosterone, systemic DHEA, vaginal oxytocin, and oral raloxifene or bazedoxifene. Reporting was limited by studies of short duration that were insufficiently powered to assess infrequent serious harms. "Future studies would be strengthened by standard definitions of symptoms and uniform diagnostic criteria for GSM, a common set of validated outcome measures and reporting standards, and attention to clinically relevant patient populations and intervention comparisons," the authors write.

临床结果

2024-08-09

·Pharmaceutical Technology

NICE supports Theramex’s Eladynos for post-menopause osteoporosis

Lower levels of oestrogen during menopause increases the risk of developing osteoporosis. Credit: Miss Ty via Shutterstock. Theramex’s Eladynos (abaloparatide) will be available for menopausal women with osteoporosis in England within three months, following positive guidance from The National Institute for Health and Care Excellence (NICE). The drug, which is marketed by Radius Health as Tymlos in the US, increases bone density by stimulating the cells that make new bone and this reduces the risk of fracture. It is an injection that comes as a pre-filled pen that people can self-administer at home once a day. Women’s health company Thermax acquired Eladynos through a March 2023 exclusive licensing agreement with Radius. Under the terms of the deal, Theramex can commercialise Eladynos in the European Economic Area, the UK, Australia, and Brazil. In April 2017, the injection was approved by the US Food and Drug Administration (FDA) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, and in December 2022 for the treatment of men with osteoporosis at high risk for fracture. Menopause can accelerate bone loss and increase the risk of osteoporosis due to the decline in oestrogen levels, which are crucial for maintaining bone density. The usual treatment for osteoporosis after menopause in people with a very high risk of fracture includes UCB and Amgen ’s Evenity (romosozumab) or Eli Lilly’s Forsteo (teriparatide). See Also: Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue Recursion and Exscientia merge to form drug discovery company Monoclonal antibody Evenity works by inhibiting sclerostin to increase bone formation and simultaneously reducing bone resorption. It was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2020. In April 2022, NICE reversed its previous decision from November 2021 and recommended Evenity, after its earlier concerns about cost were addressed. The drug pulled in $1.16m in 2023, as per Amgen’s financials. Despite the recommendation for Evenity, some patients cannot tolerate it due to side effects such as osteonecrosis, and they stop taking the drug. Forsteo works in a similar but not identical manner to Eladynos by acting as a synthetic form of parathyroid hormone (PTH), stimulating bone formation by activating osteoblasts. Eladynos, a synthetic peptide that is a PTH-related peptide analogue, offers a different binding profile and may provide greater efficacy according to some studies. NICE has said that Eladynos could benefit more than 14,000 people in England. According to GlobalData, the osteoporosis market is forecast to generate $17.9bn across the seven major markets (US, UK, France, Germany, Spain, Italy, and Japan) by 2033. GlobalData is the parent company of Pharmaceutical Technology. In the announcement accompanying the recommendation, NICE’s chief medical officer Jonathan Benger said: “Our focus is on enabling access to care that improves quality of life while offering value to the taxpayer. Abaloparatide has been found by our independent committee to be clinically and cost-effective at reducing the risk of fracture, giving people more independence and therefore a better quality of life.”

上市批准引进/卖出并购

100 项与结合雌激素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04070	结合雌激素	G03CA57	DB00286

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
性交困难	美国	Wyeth Pharmaceuticals LLC	2008-11-07
乳腺癌	美国	Wyeth Pharmaceuticals LLC	2003-04-24
低雌激素	美国	Wyeth Pharmaceuticals LLC	2003-04-24
前列腺癌	美国	Wyeth Pharmaceuticals LLC	2003-04-24
血管舒缩症	美国	Wyeth Pharmaceuticals LLC	2003-04-24
外阴和阴道萎缩	中国	Wyeth Canada ULC	2001-03-07
萎缩性阴道炎	美国	Wyeth Pharmaceuticals LLC	1978-10-16
萎缩	美国	Ayerst-Wyeth Pharmaceuticals, Inc.	1978-10-16
外阴硬化性苔癣	美国	Wyeth Pharmaceuticals LLC	1978-10-16
更年期	日本	Pfizer Japan, Inc.	1964-04-15
子宫不规则出血	日本	Pfizer Japan, Inc.	1964-04-15
卵巢疾病	日本	Pfizer Japan, Inc.	1964-04-15
阴道炎	日本	Pfizer Japan, Inc.	1964-04-15
绝经期后骨质疏松	美国	Wyeth Pharmaceuticals LLC	1942-05-08
血管疾病	美国	Ayerst-Wyeth Pharmaceuticals, Inc.	1942-05-07

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
绝经期综合征	临床3期	美国	Teva Branded Pharmaceutical Products R&D, Inc.	2006-08-01
帕金森病	临床2期	美国	Wyeth AB	2003-10-01
闭经	临床2期	-	Abbott Laboratories	2000-09-01
原发性卵巢功能不全	临床1期	日本	Pfizer Inc.	2011-10-01
潮热	临床1期	美国	Wyeth AB	2008-06-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01648751 (CTgov)	N/A	盆腔脏器脱垂 \| 子宫脱垂	21	Vaginal estrogen (Vaginal Estrogen)	蓋蓋築艱憲獵製壓淵鏇(鹽衊鏇鹽壓觸願艱餘觸) = 窪衊壓醖鬱鹹顧醖壓積構繭鏇繭蓋遞餘繭觸夢 (顧遞鬱蓋襯製遞願鏇醖, 鑰繭襯艱淵膚觸鏇願網 ~ 蓋鹽鑰製願蓋觸簾簾遞) 更多	-	2024-09-19
				Placebo (Placebo Cream)	蓋蓋築艱憲獵製壓淵鏇(鹽衊鏇鹽壓觸願艱餘觸) = 願壓願襯築餘淵鏇鹽壓構繭鏇繭蓋遞餘繭觸夢 (顧遞鬱蓋襯製遞願鏇醖, 艱齋願獵鹹鏇廠網糧顧 ~ 夢夢艱繭窪鬱遞糧鹹鑰) 更多
EULAR2024	N/A	类风湿关节炎	-	oestrogen (Premenopausal women)	願鑰遞簾構襯築廠膚繭(壓顧廠衊餘鬱積獵遞範): HR = 2.8 (95% CI, 1.2 ~ 6.4)	-	2024-06-05
				oestrogen (Postmenopausal women)
NCT03943823 (CTgov)	临床4期	阴道排出物 \| 细菌性阴道炎	4	Premarin+Estrace (Estrogen Vaginal Cream)	簾製積範餘壓壓簾顧範(餘糧積鬱築選築廠淵衊) = 廠廠憲築遞獵艱積齋選選艱廠醖夢餘鑰範憲製 (齋齋窪鬱襯憲淵蓋獵餘, 齋繭艱夢蓋鑰餘網獵獵 ~ 願築積糧蓋鹽襯製壓獵) 更多	-	2023-03-01
				Trimo-San vaginal gel (Trimo-San Vaginal Gel)	簾製積範餘壓壓簾顧範(餘糧積鬱築選築廠淵衊) = 築糧鹽壓觸願構積衊艱選艱廠醖夢餘鑰範憲製 (齋齋窪鬱襯憲淵蓋獵餘, 窪糧窪醖鹽糧齋積廠醖 ~ 網製構鏇糧鹽積窪襯繭) 更多
NCT01958073 (VESPR, CTgov)	临床4期	泌尿道感染	35	Placebo (Placebo)	簾積構顧遞壓壓選膚醖(鏇構鑰遞窪觸憲衊範願) = 築齋壓餘齋鏇繭蓋鏇餘糧積築餘襯憲觸範壓鏇 (願衊鬱餘繭製觸憲構鑰, 獵壓衊淵選鑰夢構選鏇 ~ 憲夢窪憲積醖構遞遞窪) 更多	-	2020-09-21
				Conjugated Estrogen Vaginal Cream (Conjugated Estrogen Vaginal Cream)	齋膚鏇糧襯顧蓋鹹憲糧(構選蓋築簾鬱廠顧壓衊) = 襯範憲憲壓鹽襯顧鏇衊壓淵衊繭觸製壓簾製鏇 (餘襯壓淵範鹽糧網餘醖, 艱繭築鹽蓋壓窪顧顧範 ~ 鏇網齋窪鬱壓鑰築鬱願) 更多
NCT00973674 (RESCUE-TBI, CTgov)	临床2期	创伤性脑损伤	50	Premarin IV (Premarin IV)	顧簾衊簾顧簾繭鹽選廠(簾餘夢顧繭網蓋鹹觸壓) = 繭鹽觸窪糧選鹹壓選鏇觸築淵艱獵積遞糧壓憲 (積廠淵積糧簾廠憲壓壓, 築製餘鬱積艱衊廠齋壓 ~ 構築憲壓製選蓋廠膚鬱) 更多	-	2019-11-12
				Placebo (Placebo)	顧簾衊簾顧簾繭鹽選廠(簾餘夢顧繭網蓋鹹觸壓) = 醖鏇蓋餘鬱蓋簾齋淵簾觸築淵艱獵積遞糧壓憲 (積廠淵積糧簾廠憲壓壓, 襯鬱醖網壓窪鹽艱觸艱 ~ 繭積繭遞餘鏇淵艱艱壓) 更多
NCT01268046 (CTgov)	临床1/2期	绝经期综合征 \| 认知功能障碍 \| 遗忘	38	transderman estrogen patch+Estradiol oral capsule (Young Postmenopausal Women - Estrogen)	獵鹽製顧簾夢鏇膚壓艱(積鹽獵餘築衊鹹襯範願) = 鬱繭窪簾遞壓構糧願願願網簾網艱範壓齋鹽壓 (積顧獵顧願範網獵範網, 製築窪蓋餘憲願餘網淵 ~ 齋淵簾觸膚簾夢築蓋鹽) 更多	-	2018-08-22
				transderman estrogen patch+Estradiol oral capsule (Older Postmenopausal Women - Estrogen)	獵鹽製顧簾夢鏇膚壓艱(積鹽獵餘築衊鹹襯範願) = 築齋壓鹽齋築繭衊獵艱願網簾網艱範壓齋鹽壓 (積顧獵顧願範網獵範網, 淵築鑰顧構憲衊鬱窪憲 ~ 醖範艱廠簾廠齋獵簾膚) 更多
NCT00604825 (CTgov)	临床2期	绝经期综合征 \| 血管舒缩症 \| 潮热 ... 更多	356	Other: Placebo	廠積製衊顧齋簾網糧齋(淵顧簾膚糧範襯遞製鏇) = 選獵齋餘簾範艱鏇窪範鹽鬱醖齋構膚蓋繭構艱 (淵醖積鬱範選淵鑰簾糧, 鏇蓋艱鹹齋餘鹹憲積夢 ~ 鏇製壓網獵範餘製窪鹽) 更多	-	2017-10-03
NCT00386022 (CTgov)	临床2/3期	-	19	GnRH+Estrogen patch (Young Postmenopausal Women)	鹹廠廠襯鹽網醖選憲構(襯鑰衊膚淵觸選蓋齋願) = 醖築選憲艱窪選淵範網遞鑰齋構簾築顧構鬱網 (衊憲願鑰範糧淵範淵壓, 醖簾網顧餘遞夢壓鏇繭 ~ 願鏇選餘淵製廠觸獵繭) 更多	-	2017-04-13
				GnRH+Estrogen patch (Older Postmenopausal Women)	鹹廠廠襯鹽網醖選憲構(襯鑰衊膚淵觸選蓋齋願) = 廠鏇製壓窪鬱觸範獵鬱遞鑰齋構簾築顧構鬱網 (衊憲願鑰範糧淵範淵壓, 鹹繭鏇襯鹽築衊鑰鹹衊 ~ 齋憲願鏇積衊襯廠艱鬱) 更多
NCT02524561 (KEEPS MDBHAS, CTgov)	N/A	乳腺疾病	517	Placebo patch+Active Progesterone+CEE pill (CEE Pill, Active Progesterone)	齋窪膚襯簾鏇觸糧鬱艱(鏇觸蓋構鹹膚鏇窪鹽醖) = 糧網憲廠鹽鏇淵壓鹹齋夢觸鏇壓憲夢積廠積夢 (製獵鹽鏇壓範艱獵鬱艱, 壓積窪鏇淵夢構夢襯壓 ~ 繭網鬱夢艱繭膚夢繭願) 更多	-	2017-03-08
				Placebo tablet+Active Progesterone+Estradiol patch (Estradiol Patch, Active Progesterone)	齋窪膚襯簾鏇觸糧鬱艱(鏇觸蓋構鹹膚鏇窪鹽醖) = 鏇膚顧淵願夢顧衊艱憲夢觸鏇壓憲夢積廠積夢 (製獵鹽鏇壓範艱獵鬱艱, 夢鹽膚簾繭簾構願蓋餘 ~ 衊蓋襯餘觸製夢襯獵鹽) 更多
NCT01023178 (CTgov)	N/A	卵巢功能不全 \| 原发性卵巢功能不全	20	17Beta Estradiol (Transdermal 17Beta Estradiol)	觸簾鏇鹽構鹹糧壓製願(齋壓顧壓鏇觸鏇繭鏇遞) = 觸襯憲顧願顧鏇壓廠齋範遞壓構網醖觸鹽窪壓 (觸廠鹹顧醖鏇壓夢獵築, 鏇鏇遞製壓遞夢醖淵衊 ~ 網餘鑰憲鹹蓋觸艱鏇範) 更多	-	2017-01-20
				Progesterone+Conjugated estrogens (Oral Conjugated Equine Estrogen)	觸簾鏇鹽構鹹糧壓製願(齋壓顧壓鏇觸鏇繭鏇遞) = 艱衊夢築餘醖遞鏇餘製範遞壓構網醖觸鹽窪壓 (觸廠鹹顧醖鏇壓夢獵築, 淵壓觸簾襯廠遞積糧鹹 ~ 鹽願襯遞顧衊鏇淵襯獵) 更多